Literature DB >> 24908414

Aberrant promoter methylation of p15 (INK⁴b) and p16 (INK⁴a) genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis.

Xuan Wang1, Yan-Bin Zhu, Hai-Peng Cui, Ting-Ting Yu.   

Abstract

We carried out the current meta-analysis aiming to comprehensively assess the potential role of p15 (INK4b) and p16 (INK4a) aberrant promoter methylation in the pathogenesis of multiple myeloma (MM). The MEDLINE (1966 ~ 2013), Cochrane Library (Issue 12, 2013), EMBASE (1980 ~ 2013), CINAHL (1982 ~ 2013), Web of Science (1945 ~ 2013), and Chinese Biomedical (CBM) (1982 ~ 2013) databases were searched without language restrictions. Meta-analyses were conducted using Stata software (Version 12.0, Stata Corporation, College Station, TX, USA). Odds ratios (ORs) and their 95 % confidence intervals (95 %CIs) were calculated. Thirteen clinical case-control studies, which enrolled a total of 465 MM patients and 180 healthy subjects, were included in the meta-analysis. The results of our meta-analysis demonstrated that the frequencies of p15 (INK4b) and p16 (INK4a) promoter methylation in cancer samples were significantly higher than in normal samples (p15 (INK4b) : OR = 6.26, 95 %CI = 3.87 ~ 10.12, P < 0.001; p16 (INK4a) : OR = 2.26, 95 %CI = 1.22 ~ 4.20, P < 0.001). Ethnicity-stratified analysis showed that the aberrant methylation of p15 (INK4b) was significantly related with the risk of MM among both Caucasians and Asians (all P < 0.05). Furthermore, our results also illustrated a strong positive correlation between p16 (INK4a) promoter methylation and the pathogenesis of MM among Asians (OR = 5.17, 95 %CI = 3.45 ~ 7.74, P < 0.001), but not among Caucasians (P > 0.05). The current meta-analysis confirms and reinforces existing findings that p15 (INK4b) and p16 (INK4a) promoter methylation may be closely implicated in the pathogenesis of MM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24908414     DOI: 10.1007/s13277-014-2054-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

1.  Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia.

Authors:  Eleftheria Hatzimichael; Leonidas Benetatos; Aggeliki Dasoula; George Dranitsaris; Stavroula Tsiara; Ioannis Georgiou; Maria Syrrou; Justin Stebbing; Helen M Coley; Tim Crook; Konstantinos L Bourantas
Journal:  Leuk Res       Date:  2009-05-06       Impact factor: 3.156

Review 2.  Genomics in multiple myeloma.

Authors:  Nikhil C Munshi; Hervé Avet-Loiseau
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

3.  p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance.

Authors:  G Guillerm; E Gyan; D Wolowiec; T Facon; H Avet-Loiseau; K Kuliczkowski; F Bauters; P Fenaux; B Quesnel
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

4.  P16 methylation is an early event in cervical carcinogenesis.

Authors:  Lee-Wen Huang; Hun-Shan Pan; Yu-Hung Lin; Kok-Min Seow; Heng-Ju Chen; Jiann-Loung Hwang
Journal:  Int J Gynecol Cancer       Date:  2011-04       Impact factor: 3.437

5.  Occupation, exposure to chemicals, sensitizing agents, and risk of multiple myeloma in Sweden.

Authors:  Virginia Lope; Beatriz Pérez-Gómez; Nuria Aragonés; Gonzalo López-Abente; Per Gustavsson; Nils Plato; Jan-Paul Zock; Marina Pollán
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

6.  p15 promoter methylation - a novel prognostic marker in glioblastoma patients.

Authors:  Silke Wemmert; Marc Bettscheider; Simone Alt; Ralf Ketter; Kai Kammers; Wolfgang Feiden; Wolf-Ingo Steudel; Jörg Rahnenführer; Steffi Urbschat
Journal:  Int J Oncol       Date:  2009-06       Impact factor: 5.650

Review 7.  The pathogenesis of the bone disease of multiple myeloma.

Authors:  Claire M Edwards; Junling Zhuang; Gregory R Mundy
Journal:  Bone       Date:  2008-02-21       Impact factor: 4.398

8.  Methylation status of nine tumor suppressor genes in multiple myeloma.

Authors:  Esteban Braggio; Angelo Maiolino; Maria E Gouveia; Roberto Magalhães; João T Souto Filho; Márcia Garnica; Marcio Nucci; Ilana Zalcberg Renault
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

9.  Nucleosomes correlate with in vivo progression pattern of de novo methylation of p16 CpG islands in human gastric carcinogenesis.

Authors:  Zhe-Ming Lu; Jing Zhou; Xiuhong Wang; Zhenpo Guan; Hua Bai; Zhao-Jun Liu; Na Su; Kaifeng Pan; Jiafu Ji; Dajun Deng
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

Review 10.  Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing.

Authors:  Michel P Bihl; Anja Foerster; Alessandro Lugli; Inti Zlobec
Journal:  J Transl Med       Date:  2012-08-27       Impact factor: 5.531

View more
  9 in total

1.  p16 hypermethylation: a biomarker for increased esophageal cancer susceptibility in high incidence region of North East India.

Authors:  Mandakini Das; Bhaskar Jyoti Saikia; Santanu Kumar Sharma; Gaganpreet Singh Sekhon; Jagadish Mahanta; Rup Kumar Phukan
Journal:  Tumour Biol       Date:  2014-11-01

Review 2.  P15 gene methylation in hepatocellular carcinomas: a systematic review and meta-analysis.

Authors:  Wei-Hua Ren; Ya-Wei Li; Rui Li; Hong-Bo Feng; Jun-Long Wu; Hui-Rui Wang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

3.  Clinicopathological significance and potential drug target of p15INK4B in multiple myeloma.

Authors:  Jun Li; Lintao Bi; Yumei Lin; Zhenxia Lu; Gang Hou
Journal:  Drug Des Devel Ther       Date:  2014-10-31       Impact factor: 4.162

4.  Clinicopathological significance of p15 promoter hypermethylation in multiple myeloma: a meta-analysis.

Authors:  Bing Wei; Shuhua Yang; Bo Zhang; Yong Feng
Journal:  Onco Targets Ther       Date:  2016-07-01       Impact factor: 4.147

5.  Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Authors:  C Pawlyn; M D Bright; A F Buros; C K Stein; Z Walters; L I Aronson; F Mirabella; J R Jones; M F Kaiser; B A Walker; G H Jackson; P A Clarke; P L Bergsagel; P Workman; M Chesi; G J Morgan; F E Davies
Journal:  Blood Cancer J       Date:  2017-03-31       Impact factor: 11.037

Review 6.  Quantitative assessment of aberrant P16INK4a methylation in ovarian cancer: a meta-analysis based on literature and TCGA datasets.

Authors:  Jie Ruan; Peipei Xu; Wei Fan; Qiaoling Deng; Mingxia Yu
Journal:  Cancer Manag Res       Date:  2018-08-29       Impact factor: 3.989

7.  Indirect Tumor Inhibitory Effects of MicroRNA-124 through Targeting EZH2 in The Multiple Myeloma Cell Line.

Authors:  Javid Sabour Takanlu; Arad Aghaie Fard; Saeed Mohammdi; Seyed Mohammad Ali Hosseini Rad; Saeid Abroun; Mohsen Nikbakht
Journal:  Cell J       Date:  2019-09-08       Impact factor: 2.479

8.  The epigenetic impact of suberohydroxamic acid and 5‑Aza‑2'‑deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL‑6 expression.

Authors:  Katerina Smesny Trtkova; Petra Luzna; Denisa Weiser Drozdkova; Katerina Cizkova; Lucie Janovska; Jan Gursky; Dana Prukova; Ivo Frydrych; Marian Hajduch; Jiri Minarik
Journal:  Mol Med Rep       Date:  2022-08-31       Impact factor: 3.423

Review 9.  Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update.

Authors:  Eleftheria Hatzimichael; Konstantinos Lagos; Van Ren Sim; Evangelos Briasoulis; Tim Crook
Journal:  EXCLI J       Date:  2014-08-26       Impact factor: 4.068

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.